PUCOTENLIMAB + Becotatug Vedotin for penile neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Apr 2026: Trial registered, NCT07518979
  2. 22 Jul 2026: Trial started, NCT07518979

The trials

NCT07518979: EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer

State
Under way
Phase
Phase 2
People
60 planned
Started
22 Jul 2026
Primary completion
1 May 2028
Arms
Becotatug Vedotin + Pucotenlimab Neoadjuvant Arm
Results
None posted
  1. 9 Apr 2026: Trial registered
  2. 22 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.